BioWorld

Nov. 28, 2005

View Archived Issues

Alexion's Heart Drug Fizzles In Second Phase III CABG Study

Bad pre-holiday news from the Phase III trial with pexelizumab gave investors in Alexion Pharmaceuticals Inc. little cause to be thankful, and Wall Street took away more than a fourth of the stock's value. (BioWorld Today) Read More

Required New Trial Of Vasovist Drops EPIX's Stock 14 Percent

Read More

Something Old, Something New In Anxiolytics Research

Read More

Price Control Lawsuit Heard But Again Delayed In Federal Court

Read More

Holiday Notice

Read More

Other News To Note

Read More